Hou et al. (2020) found that correcting the abnormal signal of miR-124/PTPN1 can save the pathology of tau in AD, which implies the key role of miR-124/PTPN1 in the progression of AD. Ansari et al. (2019) provided evidence of miR-146a and miR-181a as biomarkers for AD diagnosis. The gene discussed is MAPT; the disease is Alzheimer disease.